Science

Bisantrene is a small molecule anti-cancer drug which has potential as both a low dose, highly targeted precision oncology agent and a high dose, less cardiotoxic chemotherapeutic. History of Bisantrene Bisantrene was originally developed by Lederle Pharmaceutical  in the 1970s as a lower cardiotoxic alternative to the anthracyclines. Lederle trialled Bisantrene on a wide range of cancers in the 1980s (more than 40 clinical trials) and it showed particular promise in leukemias, breast cancer and ovarian cancer. Bisantrene was studied in a large Phase III breast cancer trial in the…

Latest News

+

Race Oncology Limited (ASX: RAC) is pleased to release an extended version of the presentation from our 2020 Annual General…

Race Oncology is pleased to release our updated strategic plan for the clinical advancement of Bisantrene at our 2020 AGM.…

10 November 2020 – Race Oncology Limited (ASX: RAC) is pleased to report that the clinical data from the investigator…